This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $70.19, moving +0.07% from the previous trading session.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $71.46 in the latest trading session, marking a +0.75% move from the prior day.
Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $68.20, moving +0.47% from the previous trading session.
Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $68.32, marking a +0.66% move from the previous day.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $75.65, marking a -1.27% move from the previous day.
Shockwave Medical (SWAV) Up 35.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $75.99, moving +1.8% from the previous trading session.
Why Is Hologic (HOLX) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) Gets CE Mark for Fusion Molecular Assays
by Zacks Equity Research
Hologic's (HOLX) two new molecular assays monitor transplant patients for EBV and BKV.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
If You Invested $1000 in Hologic a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.
Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 33.55% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stock Earnings Roster for Apr 27: BSX, HOLX & More
by Riya Anand
Medical device stocks' Q1 earnings will likely reflect rebound in base business. Let's see how Boston Scientific (BSX), Hologic (HOLX), Align Technology (ALGN) and Integra (IART) will fare in Q1.
Is a Surprise Coming for Hologic (HOLX) This Earnings Season?
by Zacks Equity Research
Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and GYN Surgical businesses is likely to have contributed to Hologic's (HOLX) fiscal second-quarter revenues.
Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.